<DOC>
	<DOC>NCT00789867</DOC>
	<brief_summary>The study objectives are to assess safety, tolerability and gene expression after a single dose of non-viral CFTR gene therapy (pGM169/GL67A) administered to the nose and lungs of patients with cystic fibrosis.</brief_summary>
	<brief_title>Single Dose of pGM169/GL67A in CF Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Cystic fibrosis confirmed by sweat testing or genetic analysis Males and females aged 16 years and above Forced expiratory volume in the 1st second (FEV1) &gt; 60% predicted values Clinical stability at entry Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter If taking regular rhDNase (pulmozyme) is willing, and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose Written informed consent obtained Permission to inform GP of participation in study Infection with Burkholderia cepacia complex organisms or MRSA Significant nasal pathology including polyps, clinicallysignificant rhinosinusitis, or recurrent severe epistaxis (nose bleeds) Acute upper respiratory tract infection within the last 2 weeks Previous spontaneous pneumothorax without pleurodesis Recurrent severe haemoptysis Current smoker Significant comorbidity including: 1. Moderate/severe CF liver disease 2. Significant renal impairment 3. Significant coagulopathy Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Single dose</keyword>
	<keyword>Pilot</keyword>
	<keyword>Safety</keyword>
	<keyword>Gene expression</keyword>
	<keyword>Tolerability</keyword>
	<keyword>CFTR gene</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Non-viral</keyword>
</DOC>